PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Budesonide - Inflammatory bowel disease

PAD Profile : Budesonide - Inflammatory bowel disease Important

Keywords :
Ulcerative colitis, UC, IBD, protitis, procto sigmoiditis, ulcerative proctitis
Brand Names Include :
Budenofalk
Important Information :
Steroid safety considerations

Traffic Light Status

Status 1 of 3.

Status :
Green
Formulations :
  • Foam enema
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
SA
Comments :
No comments returned.
Documents :

Status 2 of 3.

Status :
Red
Important
Formulations :
  • Modified release capsules
Important Information :
3mg MR capsules - gastroenterology team only
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 3 of 3.

Status :
N/A
Important
Formulations :
  • Suppositories
Important Information :
Not assessed for formulary status. Applications for formulary entry via APC.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 February 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Please see the attached pathway which has been developed in conjunction with local specialists for the GP management of adult patients with known ulcerative colitis . 

13 March 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Budenofalk (budesonide) rectal foam as a treatment option for patients with active Ulcerative Colitis Budenofalk (budesonide) rectal foam will be considered GREEN on the traffic light system Primary care prescribers should consider switching patients to budesonide rectal foam and for all new patients to use budesonide rectal foam moving forwards.
02 October 2024
Not Set

Budesonide SUPPOSITORIES: have not yet been assessed for formulary status and is not currently on the APC work-plan.

This formulation has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.02. Corticosteroids
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More